ANTENGENE-B(06996): ATG-201 has received HREC approval in Australia for the I phase ATTRACT study for the treatment of B cell-mediated autoimmune diseases.

07:00 25/08/2026

Deqi Medical-B (06996) announced that the Board of Directors is pleased to declare that the Phase I ATTRACT study of ATG-201 (a CD19/CD3 bispecific T cell engager antibody developed by the group for the treatment of B cell-related autoimmune diseases) has obtained approval from the Human Research Ethics Committee (HREC) of Australia, and the process of submitting the Clinical Trial Notification (CTN) to the Therapeutic Goods Administration (TGA) has been completed.

ANTENGENE-B (06996) announced that the company's board of directors is pleased to announce that the Group's independently developed ATG-201 (a CD19/CD3 bispecific T cell engager antibody for the treatment of B cell-related autoimmune diseases) has received approval from the Human Research Ethics Committee (HREC) of Australia, and the clinical trial notification (CTN) has been successfully submitted to the Therapeutic Goods Administration (TGA).

Apple Inc. (AAPL.US) is set to launch its first brand-new Mac mini in two years, with multiple new products in the pipeline.

The disparity in per capita AI investment is significant. How can ABLE DIGITAL (02687) fill the gap?

YUNJI (02670) has applied for the proposal to implement full circulation of H-shares, which has been approved by the Stock Exchange of Hong Kong.

Apple Inc. (AAPL.US) is set to launch its first brand-new Mac mini in two years, with multiple new products in the pipeline.

The disparity in per capita AI investment is significant. How can ABLE DIGITAL (02687) fill the gap?

YUNJI (02670) has applied for the proposal to implement full circulation of H-shares, which has been approved by the Stock Exchange of Hong Kong.